

The results should be confirmed in prospective studies and in a large number of patients. It is expected that in such studies the response rate, MTP and MST will be substantially lower than in the CAN-1 study. In order to systematically test antineoplastons in different types of brain tumours, the Burzynski Research Institute is sponsoring an additional 23 prospective phase II clinical trials in brain tumours under Investigational New Drug Applications filed with the FDA. The results of these trials will be published as soon as they are completed.

Acknowledgements

This study was sponsored by the Burzynski Research Institute and supervised by its Institutional Review Board (IRB). The membership of the IRB was in agreement with the FDA.

The authors express their appreciation to Lucy Rorke, MD, Professor of Pathology, University of Pennsylvania, Children's Hospital of Philadelphia, for review of pathology slides; Dieter Schellinger, MD, Professor of Radiology, Chief, Section of Neuroradiology, Georgetown Hospital, Washington, DC, and Marion A. Jabczynski, MD, for evaluation of MRI films; and Peter Silberstein, MD, Senior Paediatric Neurologist, Princess Margaret Hospital, Perth, Australia, for follow-up and evaluation of Australian patients.

The following additional medical doctors at the Burzynski Clinic participated in the study: Barbara Burzynski, Jaroslaw K. Paszkowiak, Tomasz J. Janicki, Vishnu B. Alapati, Barbara E. Drynia, Wojciech Z. Iwanowski, Gabor F. Jurida, Mohammed I. Khan, Eva Kubove, Grace A. Ormstein, Jacek J. Paszkowiak, Mohammed C. Radmard, Basel I. Salhoot, and Barbara G. Szymkowski.

References

- Burzynski SR. Purified antineoplaston fractions and methods of treating neoplastic disease. US Patent No. 4,470,970. 1984
- Burzynski SR. Synthetic antineoplastons and analogs. *Drugs Future* 1986; 11: 679-88
- Burzynski SR. Potential of antineoplastons in diseases of old age. *Drugs Aging* 1995; 7 (3): 157-67
- Hawkins MG, Friedman MA. National Cancer Institute's evaluation of unconventional cancer treatments. *J Natl Cancer Inst* 1992; 84: 1699-702
- Burzynski SR, Kubove E, Burzynski B. Phase II clinical trials of Antineoplastons A10 and AS2-1 infusions in astrocytoma. In: Adam D, Buchner T, Rubinstein E, editors. Recent advances in chemotherapy. Munich: Futuramed Publishers, 1991: 2506-07
- Burzynski SR, Kubove E, Szymkowski B. Phase II clinical trials of Antineoplastons A10 and AS2-1 infusions in high grade glioma. Presented at the 18th International Congress of Chemotherapy; 1993 Jun 27-Jul 2: Stockholm, Sweden
- Eriguchi N, Tsuda H, Hara H, et al. The effect of antineoplastons A10, AS2-1 on brain tumors. In: Adam D, Buchner T, Rubinstein E, editors. Recent advances in chemotherapy. Munich: Futuramed Publishers, 1991: 2504-5
- Tsuda H, Sugita Y, Sugita N, et al. Effect of Antineoplaston AS2-1 on high grade glioma. Presented at the 18th International Congress of Chemotherapy; 1993 Jun 27-Jul 2: Stockholm, Sweden
- Sugita Y, Tsuda H, Maruiwa H, et al. The effect of antineoplaston, a new antitumor agent, on malignant brain tumors. *Kurume Med J* 1995; 42: 133-40
- Elias T. The Burzynski Breakthrough. Santa Monica, CA: General Publishing Group; 1997
- Lerner M. Stanislaw Burzynski - antineoplastons on the edge of medical credibility. In: Lerner M, editor. Choices in healing. Cambridge, MA: MIT Press; 1994
- Smith MEG. The Burzynski controversy in the United States and in Canada: a comparative case study in the sociology of alternative medicine. *Can J Sociol* 1992; 17: 133-60
- Samid D, Sherman L, Rimoldi D. Induction of phenotypic reversion and terminal differentiation in tumor cells by antineoplaston AS2-1. Presented at the 9th International Symposium on Future Trends in Chemotherapy; 1990 March 26-28, Geneva, Switzerland
- Samid D, Yeh TJ, Shack S. Interferon in combination with anti-tumorigenic phenyl derivatives: potentiation of α -IFN activity *in vitro*. *Br J Haematol* 1991; 79 Suppl. 1: 81-3
- Samid D, Shack S, Sherman LT. Phenylacetate: a novel non-toxic inducer of tumor cell differentiation. *Cancer Res* 1992; 52: 1988-92
- Thibault A, Cooper MR, Figg WD, et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. *Cancer Res* 1994; 54: 1690-4
- Thibault A, Samid D, Cooper MR, et al. Phase I study of phenylacetate administered twice daily to patients with cancer. *Cancer (Phila)* 1995; 75: 2932-8
- Shack S, Chen LC, Miller AC, et al. Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21^{ras} isoprenylation and phenotypic reversion. *Int J Cancer* 1995; 63: 124-9
- Adam L, Crepin M, Savin C, et al. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7 ras cells *in vitro* and in nude mice. *Cancer Res* 1995; 55: 5156-60
- Liu L, Samid D. Mutant p53 as a target of phenylacetate in human glioblastoma. Presented at the 86th Annual Meeting of the American Association for Cancer Research; 1995 March 18-22; Toronto, Canada
- Gorospe M, Shack S, Guyton KZ, et al. Up-regulation and functional role of p21^{Waf1/Cip1} during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. *Cell Growth Differ* 1996; 7: 1609-15
- Sandberg-Wollheim M, Malmerström P, Strömblad LG, et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grade 3 and/or 4. *Cancer* 1991; 68: 22-9
- Hildebrand J, Sahnoud T, Mignolet F, et al. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. *Neurology* 1994; 44: 1479-83
- Jeremic B, Grujicic D, Jevremovic S, et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a Phase II study. *J Clin Oncol* 1992; 10: 1074-7